Watch: As Opioid Settlement Money Starts to Flow, States and Local Officials Debate How to Use It
PBS NewsHour featured KFF Health News’ Aneri Pattani as it reported on how this debate is playing out in North Carolina and Ohio.
Drugs
221 - 240 of 1,290 Results
-
-
New Alzheimer’s Drug Raises Hopes — Along With Questions
Clinics serving Alzheimer’s patients are working out the details of who will get treated with the new drug Leqembi. It won’t be for everyone with memory-loss symptoms.
On Abortion Rights, Ohio Is the New Kansas
Episode 309Nearly a year to the day after Kansas voters surprised the nation by defeating an anti-abortion ballot question, Ohio voters defeated a similar, if cagier, effort to limit access in that state. This week, they rejected an effort to raise the threshold for approval of future ballot measures from a simple majority, which would have made it harder to protect abortion access with yet another ballot question come November. Meanwhile, the number of Americans without health insurance has dropped to an all-time low, though few noticed. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Roubein of The Washington Post, and Emmarie Huetteman of KFF Health News join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews Kate McEvoy, executive director of the National Association of Medicaid Directors, about how the “Medicaid unwinding” is going, as millions have their eligibility for coverage rechecked.
-
Seeking Medicare Coverage for Weight Loss Drugs, Pharma Giant Courts Black Influencers
Novo Nordisk, the dominant company in the multibillion-dollar market for weight loss drugs, focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease that needs treatment.
-
Survey: Americans Want Weight Loss Drugs Despite High Cost
A new poll reveals enthusiasm for a pricey new generation of weight loss drugs, but interest drops if users potentially have to deal with weekly injections, lack of insurance coverage, or a need to continue the medications indefinitely to avoid regaining weight.
-
The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers
The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors at risk of Alzheimer’s, experts say.
By Arthur Allen Another Try for Mental Health ‘Parity’
Episode 307President Joe Biden is kicking off his reelection campaign in part by trying to finish a decades-long effort to establish parity in insurance benefits between mental and physical health. Meanwhile, House Republicans are working to add abortion and other contentious amendments to must-pass spending bills. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Céline Gounder about her podcast “Epidemic.” The new season focuses on the successful public health effort to eradicate smallpox.
-
New Weight Loss Drugs Carry High Price Tags and Lots of Questions for Seniors
Although nearly 40% of Americans 60 and older are obese, Medicare doesn’t cover weight loss medications. Meanwhile, studies haven’t thoroughly examined new drugs’ impact on older adults.
Let’s Talk About the Weather
Episode 306It’s been the summer of broken weather records around the world — for heat, rain, and wildfire smoke — advertising the risks of climate change in a big way. But, apparently, it’s not enough to break the logjam in Washington over how to address the growing climate crisis. Meanwhile, in Texas, women who were unable to get care for pregnancy complications took their stories to court, and Congress gears up to — maybe — do something about prescription drug prices. Alice Miranda Ollstein of Politico, Shefali Luthra of The 19th, and Rachel Cohrs of Stat join Julie Rovner, KFF Health News’ chief Washington correspondent, to discuss these issues and more. Also this week, Rovner interviews Meena Seshamani, the top administrator for the federal Medicare program.
-
Once the New Over-the-Counter Birth Control Pill Is Available, What About Cost and Coverage?
The Food and Drug Administration’s approval is viewed as groundbreaking, but many details still must be figured out.
Wait, What’s a PBM?
Season 9, Episode 9Pharmacy benefit managers, or PBMs, are companies that negotiate the prices of prescription drugs. Hear about their role in raising drug prices and the ongoing efforts to regulate this complex industry.
-
What You Need to Know About the Drug Price Fight in Those TV Ads
At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients.
By Arthur Allen -
Why the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients
Black patients and other minorities tend to be diagnosed at later stages of the disease, which would exclude them from use of Leqembi. Few Black people were included in the main trial of the drug.
By Arthur Allen -
Patients Squeezed in Fight Over Who Gets to Bill for Pricey Infusion Drugs
To drive down costs, insurers are bypassing hospital system pharmacies and delivering high-priced infusion drugs, including some used in chemotherapy, via third-party pharmacies. Smarting from losing out on billing for those drugs, hospitals and clinics are trying to convince states to limit this practice, known as "white bagging."
-
Need to Get Plan B or an HIV Test Online? Facebook May Know About It
Twelve of the largest drugstores in the U.S. sent shoppers’ sensitive health information to Facebook or other platforms, according to an investigation by The Markup and KFF Health News.
-
The DEA Relaxed Online Prescribing Rules During Covid. Now It Wants to Rein Them In.
Supporters say the proposed rules would balance the goals of increasing access to health care and helping prevent medication misuse. Opponents say the rules would make it difficult for some patients — especially those in rural areas — to get care.
-
Drugmakers Are Abandoning Cheap Generics, and Now US Cancer Patients Can’t Get Meds
A quality-control crisis at an Indian pharmaceutical factory has left doctors and their patients with impossible choices as cheap, effective, generic cancer drugs go out of stock.
By Arthur Allen -
Tech Luminaries Give RFK Jr.’s Anti-Vaccine Message a Boost
The views of the leader of a broad anti-vaccine movement who is now running for president are unchallenged in public forums run by several prominent Silicon Valley figures.
By Darius Tahir Debt Deal Leaves Health Programs (Mostly) Intact
Episode 301The bipartisan deal to extend the U.S. government’s borrowing authority includes future cuts to federal health agencies, but they are smaller than many expected and do not touch Medicare and Medicaid. Meanwhile, Merck & Co. becomes the first drugmaker to sue Medicare officials over the federal health insurance program’s new authority to negotiate drug prices. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Lauren Weber of The Washington Post, and Jessie Hellmann of CQ Roll Call join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews KFF Health News senior correspondent Sarah Jane Tribble, who reported the latest KFF Health News-NPR “Bill of the Month” feature, about the perils of visiting the U.S. with European health insurance.
-
Many People Living in the ‘Diabetes Belt’ Are Plagued With Medical Debt
The “Diabetes Belt,” as defined by the Centers for Disease Control and Prevention, comprises 644 mostly Southern counties where diabetes rates are high. Of those counties, KFF Health News and NPR found, more than half also have high levels of medical debt.